Skip to content
10-K

Annual Report

Karyopharm Therapeutics Inc. KPTI

0001193125-26-049397

← back to feed
Filed
Feb 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 5, 2026 18.34M sh
Shares Diluted FY 2025 · Dec 31, 2025 10.94K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 8.46K sh
Shares Diluted restated FY 2025 · Dec 31, 2023 7.62K sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $142K
Capex FY 2025 · Dec 31, 2023 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$75.37M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$127.49M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$92.72M
Cash And Equivalents FY 2025 · Dec 31, 2025 $60.54M
Cash And Equivalents FY 2025 · Dec 31, 2024 $62.48M
Cash And Equivalents FY 2025 · Dec 31, 2023 $52.23M
Stockholders Equity FY 2025 · Dec 31, 2025 −$292.93M
Stockholders Equity FY 2025 · Dec 31, 2024 −$186.02M
Stockholders Equity FY 2025 · Dec 31, 2023 −$136.21M
Stockholders Equity FY 2025 · Dec 31, 2022 −$16.66M
Current Liabilities FY 2025 · Dec 31, 2025 $92.06M
Current Liabilities FY 2025 · Dec 31, 2024 $92.26M
Total Liabilities FY 2025 · Dec 31, 2025 $401.34M
Total Liabilities FY 2025 · Dec 31, 2024 $350.44M
Current Assets FY 2025 · Dec 31, 2025 $103.15M
Current Assets restated FY 2025 · Dec 31, 2024 $156.46M
Total Assets FY 2025 · Dec 31, 2025 $108.42M
Total Assets FY 2025 · Dec 31, 2024 $164.42M
Eps Diluted FY 2025 · Dec 31, 2025 −$17.93
Eps Diluted restated FY 2025 · Dec 31, 2024 −$14.00
Eps Diluted restated FY 2025 · Dec 31, 2023 −$18.79
Eps Basic FY 2025 · Dec 31, 2025 −$17.93
Eps Basic restated FY 2025 · Dec 31, 2024 −$9.41
Eps Basic restated FY 2025 · Dec 31, 2023 −$18.79
Sga Expense FY 2025 · Dec 31, 2025 $105.21M
Sga Expense FY 2025 · Dec 31, 2024 $115.44M
Sga Expense FY 2025 · Dec 31, 2023 $131.88M
Rd Expense FY 2025 · Dec 31, 2025 $125.62M
Rd Expense FY 2025 · Dec 31, 2024 $143.23M
Rd Expense FY 2025 · Dec 31, 2023 $138.75M
Net Income FY 2025 · Dec 31, 2025 −$196.04M
Net Income FY 2025 · Dec 31, 2024 −$76.42M
Net Income FY 2025 · Dec 31, 2023 −$143.1M
Operating Income FY 2025 · Dec 31, 2025 −$90.71M
Operating Income FY 2025 · Dec 31, 2024 −$119.44M
Operating Income FY 2025 · Dec 31, 2023 −$129.54M
Revenue FY 2025 · Dec 31, 2025 $146.07M
Revenue FY 2025 · Dec 31, 2024 $145.24M
Revenue FY 2025 · Dec 31, 2023 $146.03M